Adaptive Randomization of Neratinib in Early Breast Cancer
2016 · New England Journal of Medicine · 456 citations
https://doi.org/10.1056/nejmoa1513750
D
Donald W. Northfelt
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
486
Papers
11.2K
Citations
56
h-index
151
i10-index
Donald W. Northfelt is an academic researcher from Mayo Clinic in Arizona. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 56, co-authored 414 publications.
ORCID: 0000-0002-5850-0118Papers by this author
worksNeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2017 · Clinical Cancer Research · 359 citations
https://doi.org/10.1158/1078-0432.ccr-16-3206
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
2019 · Science Translational Medicine · 304 citations
https://doi.org/10.1126/scitranslmed.aax7392
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004 · JNCI Journal of the National Cancer Institute · 271 citations
https://doi.org/10.1093/jnci/djh133
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
2020 · Journal of Clinical Oncology · 108 citations
https://doi.org/10.1200/jco.19.01027
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
2021 · JAMA Oncology · 104 citations
https://doi.org/10.1001/jamaoncol.2021.3690
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat